Methods	Allocation: randomisation Blindness: double blind Duration: 36 weeks
Participants	Diagnosis: Alzheimer’s dementia. N=36 Age: Mean 72.5, SD 8.4, range 56-87 years Sex: F 15, M 17 Setting:Australia Inclusion: diagnosis of probable AD using NINCDS-ADRDA, an ADAS-Cog score of 20-45, an MMSE score of between 10-24 and having been on donepezil 5-10 mg for over six months
Interventions	Clioquinol started at 125 mg twice daily from weeks 1 to 12, 250 mg daily from weeks 13 to 24, and 375 mg twice daily from weeks 25 to 36
Outcomes	Primary outcome: change from the baseline ADAS-Cog at weeks 4, 12, 24 and 36 Secondary outcomes: ADAS-NC, MMSE, CIBIC Plasma Aß, zinc and copper levels
Notes	Plasma Aß, zinc, and copper levels were measured every 4 weeks
Risk of bias
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Details not given in the paper
Allocation concealment (selection bias)	Unclear risk	Details not given in the paper
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Study is described as double blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Study is described as double blind
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No information given on subjects who did not complete the trial
Selective reporting (reporting bias)	High risk	Subjects were stratified by “severity” for secondary analyses